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SUMMARY
The development of midbrain dopaminergic (mDA) neurons is controlled by multiple morphogens and transcription factors. However,
little is known about the role of extracellular matrix proteins in this process. Here we examined the function of roof plate-specific spon-
dins (RSPO1-4) and the floor plate-specific, spondin 1 (SPON1). Only RSPO2 and SPON1were expressed at high levels duringmDAneuro-
genesis, and the receptor LGR5 was expressed by midbrain floor plate progenitors. Surprisingly, RSPO2, but not SPON1, specifically pro-
moted the differentiation of mDA neuroblasts into mDA neurons in mouse primary cultures and embryonic stem cells (ESCs). In
addition, RSPO2 was found to promote not only mDA differentiation, but also mDA neurogenesis in human ESCs. Our results thus un-
cover an unexpected function of the matricellular protein RSPO2 and suggest an application to improve mDA neurogenesis and differ-
entiation in human stem cell preparations destined to cell replacement therapy or drug discovery for Parkinson disease.
INTRODUCTION
The development of ventral midbrain (VM) dopaminergic
(DA) neurons involves multiple parallel, controlled pro-
cesses encompassing many signaling molecules and tran-
scription factors tightly coordinated in order to produce
functional midbrain DA (mDA) neurons (reviewed in
Arenas et al., 2015). Wnt signaling has been shown to
play many essential functions in VM DA neuron develop-
ment both in vivo and in vitro, by activating both Wnt/
b-catenin-dependent and/or -independent pathways
(Arenas, 2014; Inestrosa and Arenas, 2010). In brief,
Wnt1/b-catenin-dependent signaling in the midbrain is
responsible for the specification of the mDA progenitor
domain, progenitor proliferation, and survival at late stages
(Castelo-Branco et al., 2003; Prakash et al., 2006; Ander-
sson et al., 2013).Wnt5a/b-catenin-independent signaling
is responsible for regulatingmidbrainmorphogenesis, neu-
rogenesis, and mDA precursor differentiation (Andersson
et al., 2008, 2013; Castelo-Branco et al., 2003). Other VM
Wnt/b-catenin activators include Wnt2 responsible for
increasing progenitor proliferation (Sousa et al., 2010)
and Wnt7a for progenitor proliferation, neurogenesis,
and axon morphogenesis (Fernando et al., 2014). Wnt
modulators and inhibitors including Sfrp1/2 have a role
in potentiating the Wnt/PCP signal (Kele et al., 2012),
and Dickkopf members such as Dkk1 regulate mDA differ-
entiation and morphogenesis (Ribeiro et al., 2011), while
Dkk3 promotes mDA neuron differentiation (Fukusumi
et al., 2015).
The roof plate-specific spondin (RSPO) family of secreted
matricellular Wnt modulator proteins (RSPO1-RSPO4)
show 60% amino acid homology and share similar
domain structure (de Lau et al., 2012). RSPOs contain a
thrombospondin type I repeat domain (Chen et al., 2002;
Kazanskaya et al., 2004) that is shared with spondin 1
(SPON1; floor plate spondin), which promotes neural cell
adhesion, neurite outgrowth, and nerve precursor differen-
tiation (Feinstein et al., 1999; Klar et al., 1992; Schubert
et al., 2006). RSPOs also contain two furin-like cysteine-
rich domains that are necessary to activate the Wnt/b-cat-
enin pathway (Kim et al., 2008) and to maintain the stem
cell compartments in organs such as the intestine, liver,
pancreas, kidney, and hair follicle among others (Barker
et al., 2007, 2012; Huch et al., 2013a, 2013b; Jaks et al.,
2008).
RSPOs act synergistically to activate Wnt/b-catenin (Ka-
zanskaya et al., 2004; Kim et al., 2005) by binding to the
leucine-rich repeat-containing G protein-coupled receptor
4, 5, or 6 (LGR4-6) instead of the typical WNT receptors,
frizzleds (FZDs), or the co-receptor, low-density lipoprotein
receptor-related protein 5 or 6 (LRP5/6) (Carmon et al.,
2011; Glinka et al., 2011; de Lau et al., 2011). Upon RSPO
binding to LGR, the transmembrane E3 ubiquitin ligases,
ring finger protein 43 (RNF43), or the zinc and ring finger 3
(ZNRF3), bind to RSPO (Chen et al., 2013) and become part
of the RSPO-LGR complex (Hao et al., 2012; Koo et al.,
2012). This prevents RNF43 and ZNRF3 from interacting
with the WNT-FZD complex and leads to the ubiq-
uitination and degradation of RSPO-LGR instead of the
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WNT-FZD-LRP signaling complex, thus increasing Wnt/
b-catenin signaling (de Lau et al., 2014; Zebisch and Jones,
2015). However, RSPOs have also been reported to inhibit
Wnt/b-catenin signaling (Rong et al., 2014) and to activate
Wnt/PCP signaling by binding to the heparan-sulfatepro-
teoglycan, syndecan 4 (Ohkawara et al., 2011), suggesting
that their activity may be cell context dependent.
Rspo2 has been shown to play roles in morphogenesis
of the respiratory tract as well as limb development (Bell
et al., 2008). Within the nervous system, Rspo2 expression
is regulated by the LIM homeodomain transcription factor,
Lmx1a (Hoekstra et al., 2013), a transcription factor
required for the specification of the midbrain floor plate
and mDA neuron development (Andersson et al., 2006;
Deng et al., 2011). In addition, miR135a2 has been pre-
dicted to target Rspo2 and Lmx1b. While deletion of the
Lmx1b results in reduced Wnt/b-catenin signaling and
the mDA progenitor pool (Anderegg et al., 2013), deletion
of Rspo2 resulted only in amodest decrease in the immuno-
reactivity of mDA neuron markers, such as TH (tyrosine
hydroxylase; the rate-limiting enzyme for dopamine syn-
thesis) and PITX3 (paired-like homeodomain transcription
factor 3; a transcriptional regulator of mDA neuron differ-
entiation [Maxwell et al., 2005; Nunes et al., 2003]). It is
thus at present unknown whether the development of
mDA neurons can be controlled by proteins of the RSPO
family or SPON1 and whether they can control stem cell
behavior as described in other tissues.
Here we report that Rspo2, but not Rspo1, 3, 4, or Spon1, is
dynamically expressed in the VM during the critical time
window of mDA neurogenesis. Moreover, analysis of the
function of recombinant RSPO2 protein revealed robust
positive effects on mDA differentiation that resulted in a
2-fold increase in the number of mDA neurons, not only
in primary VM cultures but also in mouse and human em-
bryonic stem cell (ESC) preparations. Thus, our results
identify RSPO2 as an efficient factor capable of promoting
mDA neuron differentiation in both mouse and human
stem cell differentiation protocols. This knowledge can be
applied to improve current human ESC-based models and
cell replacement strategies for Parkinson disease focusing
on the loss of mDA neurons.
RESULTS
Expression of Spondins in the Developing Mouse
Midbrain Floor Plate
Wefirst determined the expression of all the roof plate fam-
ily of Spondins, Rspo1-4, and the related floor plate Spon1
(hereafter collectively referred to as spondins) in the devel-
oping VM. A clear differential upregulation of the expres-
sion of only Rspo2 was detected by qPCR at embryonic
day 11.5 (E11.5), during mDA neurogenesis and differenti-
ation. All the other spondins either decreased over time
or remained relatively constant from E10.5 to E15.5 (Fig-
ure 1A). Immunohistochemistry (IHC) showed diffuse
expression of RSPO2 in the midbrain floor plate at E11.5,
which later concentrated in patches at E12.5 (Figure 1B).
TruSeq RNA sequencing (RNA-seq) of the VM between
E11.5 and E14.5 (Figure S1A) (Toledo et al., 2017a)
confirmed that Rspo2 is expressed early in mDA develop-
ment and falls at later stages. This technique also revealed
very low expression levels of Rspo1, Rspo3, and Rspo4 (less
than 1.5 reads per million, Figure S1B). In contrast, Rspo2
and Spon1 were expressed at one or two orders of magni-
tude higher, respectively (Figure 1C). The expression
pattern of Rspos in the VMwere also examined in the Allen
DevelopingMouse Brain Atlas (Allen Institute for Brain Sci-
ence, 2017), where we found that Rspo2 is clearly expressed
in mDA progenitors adjacent to mDA neurons, identified
by Th expression in the marginal zone (Figures 1D and
S1C, arrowheads). Lower expression of Rspo2 was detected
at E13.5, while other RSPOs were undetectable in the VM,
but present in other structures (Figures S1D and S1E).
Notably, Rspo2 was also detected in a subset of mDA neu-
rons of the substantia nigra pars compacta region, at post-
natal day 56 (Figure S1F) (Lein et al., 2007). Moreover, anal-
ysis of our single-cell RNA-seq dataset of the developing
mouse VM from E11.5 to E18.5 (La Manno et al., 2016) re-
vealed that Rspo2 is significantly expressed in early neural
progenitor cells and medial neuroblasts, two cells in the
mDA neuron lineage, while Spon1 was expressed in radial
glia-like cells (Figure 1E). Other spondins were either unde-
tected, expressed uniformly or in varying cell types at low
copy number (Figure S1G). We thus can conclude that
Spon1 and Rspo2 are expressed at significant levels in the
midbrain floor plate, Rspo2 being specifically expressed in
cells of the mDA lineage and dynamically regulated during
mDA neurogenesis.
Expression of Spondin Receptors in the Developing
Mouse Midbrain Floor Plate
The expression of Lgr4-6 and associated receptors were first
examined in bulk RNA-seq data obtained from the devel-
oping VM. We found that Lgr6 is expressed at very low
levels and that Lgr4 and Lgr5 were not developmentally
regulated between E11.5 and E14.5 (Figure S2A). Single-
cell RNA-seq analysis revealed significant expression of
both receptors in basal plate cells, such as radial glia 2
(Lgr4 and Lgr5) as well as lateral neuroblast 2 and GABA2
neurons (Lgr4) (Figure S2B). This result was confirmed by
IHC, which revealed the presence of immunoreactive cells
in the basal plate (Figure S2C). However, IHC for LGR5 re-
vealed amore dynamic distribution of this protein than ex-
pected (Figure 2). At E11, individual LGR5+ cells sparsely
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lining the ventricle were detected (Figure 2A, arrowheads).
At E11.5, LGR5 IHC was clearly detected in their processes,
which co-localized with the radial glia marker Nestin (NES)
(Figure 2B), but its expression decreased in cell bodies
lining the ventricle (Figure 2B, arrowheads). At E12.5, the
levels of LGR5 decreased, resulting in less LRG5+ radial
glia processes in the basal plate than in the floor plate (Fig-
ure 2C), and very few LRG5+ cell bodies (Figure 2C, arrow-
head). Analysis of the expression of the two additional
RSPO receptors, revealed low levels of Rnf43, peaking at
E11.5–E12.5, and very low or undetectable levels of Znrf3
by either bulk or single-cell RNA-seq (Figures S2D and
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Figure 1. Expression of Spondins in the Developing Ventral Midbrain
(A) Expression of Rspo(1–4) and Spon1 measured by qPCR in VM tissue from E10.5 to E15.5. Statistical analysis compared with E11.5 for
Rspo2, the rest compared with E10.5. *p < 0.05; **p < 0.01; ***p < 0.001 by ANOVA. Data presented as means ± SEM measured in a.u.,
normalized to starting time point, E10.5.
(B) Detection of RSPO2 and TH in the VM by IHC, at E11.5 and E12.5. Dashed lines delineate the ventricular cavity. Scale bars, 100 mm.
(C) Expression levels of Rspo2 and Spon1 by TruSeq RNA-seq analysis of VM tissue obtained from TH-GFP mice over time points E11.5 to
E14.5 (Toledo et al., 2017a). See also Figure S1A.
(D) E11.5 mouse VM in situ hybridization (image data from Allen Institute for Brain Science: Allen Developing Mouse Brain Atlas) for Rspo2
(solid arrowheads) and Th (open arrowheads) as a reference. Sagittal sections through the midline (upper panels) and lateral (lower
panels). Scale bars, 200 mm.
(E) Violin plots generated from single-cell RNA-seq data of the developing mouse VM. Rspo2 and Spon1 expression levels are shown across
all known cell types. Right axis shows absolute molecule counts. Gray, enriched over baseline with posterior probability >99.8%. Cell types
with enriched expression: mNProg, neuronal progenitor; mNbM, neuroblast medial; mNbML2, neuroblast mediolateral 2; mRgl1-3, radial
glia-like cells 1-3. For the rest of the nomenclature, see La Manno et al. (2016).
See also Figure S1.
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S2E). Receptors of SPON1, APP, and APOER2/LRP8 (Ho and
Su¨dhof, 2004; Hoe et al., 2005) were also expressed, as
observed through the RNA-seq data and in situ hybridiza-
tion images (Figures S2F and S2G). Thus, our results show
that the developing midbrain expresses Spondins recep-
tors, suggesting that the ligands may play a role in
development.
RSPO2, but Not RSPO1 or SPON1, Promotes the
Differentiation of Neuroblasts into mDA Neurons
We next examined the function of the two spondins ex-
pressed at higher levels during VM development, RSPO2
and SPON1. E11.5 VM primary cultures were treated for
3 days with recombinant RSPO1, RSPO2, or SPON1 (Fig-
ure 3A). We first found that the total number of cells, iden-
tified by nuclear DAPI staining, or the total number of neu-
rons in the culture, visualized by immunocytochemistry
(ICC) with the pan-neuronal marker bIII-tubulin, did not
change in the culture (Figures 3B and S3A). Accordingly,
we did not detect any change in cell death, as assessed by
active caspase-3 staining, or in the number of proliferating
cells as determined by Ki67 (Figures 3C and 3D, respec-
tively). We next examined whether the proportion of cells
in the mDA lineage changed with the treatments. Postmi-
totic cells in the mDA lineage (neuroblast and neurons),
marked by the presence of NR4A2 (nuclear receptor
subfamily 4, group A, member 2; also known as Nurr1),
showed no significant difference between the treatments
(Figure 3F). However, in cultures treated with recombinant
RSPO1 or RSPO2, but not with SPON1, a significant in-
crease in the number of TH+ mDA neurons was detected
(1.75- and 2.5-fold increase, respectively) treatment
(Figures 3G and 3E). We then examined whether this effect
was due to an increase in the proportion of postmitotic
NR4A2+ neuroblasts that differentiate into TH+ mDA neu-
rons and found that thiswas the case for RSPO2 (Figure 3H).
A
B
C
E12.5, LGR5 DAPI
E11.0, LGR5 TH DAPI
E11.5, LGR5 NES DAPI
LGR5 NES LGR5 DAPI
LGR5
LGR5 SOX2 DAPI LGR5 SOX2
LGR5
Figure 2. Identification of LGR5-Positive Cells in Early VM
Development
(A) IHC showing LGR5+ cells lining the ventricle in the VM at E11.
Right panel shows a higher magnification of LRG5+ cells in the left
panel, identified with arrowheads. Scale bars, 50 mm (left panel)
and 10 mm (right panel).
(B) LGR5 IHC at E11.5 showed less positive cells bodies (arrow-
heads) and a strong staining radial processes co-stained with
Nestin (NES), visible at intermediate (upper right) and higher
magnification (lower right). Scale bars, 100 and 20 mm (lower left
panel).
(C) LGR5 and SOX2 IHC in the VM at E12.5. Arrowhead shows spo-
radic double-positive cells in the ventricular zone (VZ), while LRG5
fibers are found to be more restricted to the VM domain. Dashed
lines delineate the floor plate. Scale bars, 100 mm (upper panels)
and 20 mm (lower panels).
See also Figure S2.
654 Stem Cell Reports j Vol. 11 j 651–664 j September 11, 2018
Day 0 Day 3
N2 Media +
Treatment
•Vehicle
•SPON1
•RSPO1
•RSPO2
0
0.2
0.4
0.6
0.8
1
1.2
Fo
ld
C
hn
ag
e
aC3/DAPI
Ve
h.
SP
ON
1
RS
PO
1
RS
PO
2
0
0.2
0.4
0.6
0.8
1
1.2
Fo
ld
C
hn
ag
e
KI67/DAPI
Ve
h.
SP
ON
1
RS
PO
1
RS
PO
2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Fo
ld
C
ha
ng
e
NR4A2/DAPI
Ve
h.
SP
ON
1
RS
PO
1
RS
PO
2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Ve
h.
SP
ON
1
RS
PO
1
RS
PO
2
Fo
ld
C
ha
ng
e
Cell Count (DAPI)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Fo
ld
C
ha
ng
e
βIII-Tubulin/DAPI
Ve
h.
SP
ON
1
RS
PO
1
RS
PO
2
0
0.5
1
1.5
2
2.5
3
3.5
Fo
ld
C
ha
ng
e
TH/NR4A2
Ve
h.
SP
ON
1
RS
PO
1
RS
PO
2
**
0
0.5
1
1.5
2
2.5
3
3.5
Fo
ld
C
ha
ng
e
TH/DAPI
Ve
h.
SP
ON
1
RS
PO
1
RS
PO
2
*
**
E11.5
A
B
C D
E
F G H
I
TH
D
A
P
I
Vehicle SPON1
RSPO1 RSPO2
0
0.5
1
1.5
2
2.5
Ve
h.
RS
PO
2
RS
PO
1
RS
PO
1 +
 R
SP
O2
W
NT
5A
RS
PO
2 +
 W
NT
5A
DK
K1
RS
PO
2 +
 D
KK
1
J
Vehicle RSPO2
RSPO1 + RSPO2
WNT5A
DKK1 DKK1 + RSPO2
WNT5A + RSPO2
RSPO1
TH βIII-Tubulin DAPI
*
**
*
TH/DAPI
Fo
ld
C
ha
ng
e
VM
Figure 3. RSPO2 Promotes Midbrain Dopaminergic Neurons Differentiation in Primary Cultures
(A) Schematic representation of the mouse primary cell culture protocol.
(B) Quantification of the total cell numbers (DAPI) and proportion of neurons (bIII-tubulin/DAPI) normalized to control (Vehicle).
(C) Quantification of ongoing cell death, measured by active caspase-3 ICC (aC3+/DAPI), showed no difference compared with Vehicle.
(D) Quantification of KI67 ICC (KI67+/DAPI) showed no difference compared with Vehicle.
(E) ICC staining showing and increase in TH+ neurons compared with DAPI after RSPO2 treatment, but not RSPO1 or SPON1. Scale bars,
50 mm.
(F) Quantification of postmitotic cells in the DA lineage, measured by NR4A2 ICC, showed no difference compared with Vehicle.
(legend continued on next page)
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We also performed expression analysis of DA genes by
qPCR in RSPO2-treated cultures (Figure S3B) and found a
significant increase in Aldh1a1 expression, a marker for
the substantia nigra pars compacta and VTA type 2 cell types
(La Manno et al., 2016), but no changes in Otx2, Lmx1a,
Nr4a2, En1, or Pitx3, suggesting a very specific role of
RSPO2 in late differentiation. Combined, our results indi-
cate that RSPO2 is the only spondin capable of promoting
the development of mDA neurons, and that it does so by
promoting the differentiation of NR4A2+ neuroblasts into
a subset of TH+ mDA neurons.
We also examined whether the activity of RSPO2 in pri-
mary cultures could be potentiated or inhibited by co-
treatment with RSPO1 or modulators or Wnt signaling.
Surprisingly we found that RSPO1 reduced the increase
in the number of TH+ neurons by RSPO2 (Figures 3I
and 3J), indicating that RSPO1 and RSPO2 have clearly
distinct activities. Moreover, we found that co-treatment
of primary cultures with either WNT5A or Dkk1, both of
which inhibit Wnt/b-catenin signaling in the VM (for re-
view see Arenas, 2014), reduced the effects of RSPO2 on
the number of TH+ cells (Figures 3I and 3J). This result
suggests that the effect of RSPO2 on mDA neurons in-
volves, at least partially, the activation of Wnt/b-catenin
signaling.
To rule out an early effect of spondins on mDA progen-
itors, we examined earlier stages of mDA neuron develop-
ment in mouse ESCs. We used a 14-day differentiation pro-
tocol and treated the cultures with either SPON1 or RSPO2
between day 5 and 11 (Figure 4A). However, neither
SPON1 nor RSPO2 showed any significant effect on cell
proliferation or cell death as shown by active caspase-3
and Ki67 immunostainings (Figures 4B and 4C). Similar
to the primary cultures, the number of postmitotic
NR4A2+ neuroblasts did not change by SPON1 or RSPO2
treatment (Figure 4D), and a significant 1.8-fold increase
in TH+ neurons was detected (Figures 4E and 4F).
Although, SPON1 induced a significant 30% decrease in
the number of TH+ cells (Figures 4E and 4F). Analysis of
the proportion of TH+ neurons being generated from
NR4A2+ neuroblasts in differentiated mouse ESCs also re-
vealed a modest decrease in DA differentiation by SPON1
and a clear increase by RSPO2 (Figure 4G). These results
thus confirm the specific role of RSPO2 in promoting the
late differentiation of mDA neuroblasts into neurons in
the developing mouse VM.
RSPO2 Promotes the Differentiation of Human ESCs
into DA Neurons and mDA neurogenesis
We next examined whether the function of RSPO2 is
conserved in humanDAneurondevelopment andwhether
RSPO2 could be used to improve the differentiation of hu-
man ESCs into mDA neurons. We first investigated the
expression of RSPO2 and SPON1 in our single-cell RNA-seq
dataset from human VM development (La Manno et al.,
2016). Interestingly, we found higher levels of expression
of RSPO2 and SPON1 in the human VM compared with
mouse and significant differences in the cell types express-
ing them. While RSPO2 is exclusively expressed in radial
glia type 1 (hRgl1), SPON1 is exclusively expressed in radial
glia type 3 (hRgl3, Figure 5A). Analysis of the expression of
the Rspo receptors by single-cell RNA-seq revealed very low
levels of LGR4-6, RNF43, and ZNRF3 (meanmolecules/cell)
and higher levels of LGR5 in different cells, including a
floor plate progenitor (hProgFPM, Figure S4A), a cell type
thought to give rise to mDA neurons (La Manno et al.,
2016). We thus decided to examine the possible role of
RSPO2 on mDA neuron development in human ESC
cultures.
Human ESCs were differentiated for 28 days as described
recently (Nolbrant et al., 2017), using a protocol that in-
cludes the use of GSK3b inhibitors to enhance the induc-
tion of human midbrain floor plate (for review see Arenas
et al., 2015). Human ESCs were treated with recombinant
RSPO2 from day 14 to 28 (Figure 5B) and characterized by
ICC and qPCR with various mDA markers (Figures 5C
and 5D). While no change was detected for OTX2,
NR4A2, or EN1, we observed a significant increase in
PITX3 and ALDH1A1 expression. We also found that the
levels of ALDH1A1 protein increased by RSPO2 treatment,
complementing thus the previous finding of decreased
levels in Rspo2/ mice (Hoekstra et al., 2013). Also, in
line with both our primary and mouse ESC cultures, we
found that RSPO2 induced no significant differences in
the total number of cells (DAPI), cell death (active cas-
pase-3), or proliferation (Ki67) in the human ESC cultures
(Figures 5E–5G). Notably, quantification of the number of
postmitotic cells in the DA lineage revealed no significant
difference in the number of NR4A2+ cells (Figures 5E and
5H), but a significant z1.8-fold increase in the number
of TH+ neurons treated with RSPO2 (Figures 5E and 5I).
A significant z1.2-fold increase in the proportion of
NR4A2+ cells that became TH+ was detected (Figure 5J),
(G) Bar plots showing that RSPO2 treatment increases the total number of TH+ cells (TH/DAPI), compared with control (Vehicle).
(H) Normalized ratio of TH+ cells/NR4A2+ cells revealed an increase in the proportion of postmitotic dopaminergic cells (NR4A2+)
becoming mDA neurons (TH+).
(I) ICC staining of cells treated with various Wnt signaling pathway modifiers, stained with TH and bIII-tubulin. Scale bars, 50 mm.
(J) Quantification of TH+ cells in various treatments from (I) as compared with Vehicle.
All data normalized to control (Vehicle) presented as means ± SEM. n = 3, t test; *p < 0.05, **p < 0.01. See also Figure S3.
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suggesting that RSPO2 also promotes the differentiation of
neuroblasts into mDA neurons. However, this increase was
not sufficient to explain the z1.8-fold increase in TH+
cells, and suggested the involvement of an additional up-
stream mechanism. To mark proliferating progenitors, we
performed a 5-ethynyl-2’-deoxyuridine (EdU) pulse-chase
experiment and examined whether they undergo neuro-
genesis as identified by the presence of cells double-positive
for EdU and TH. Our results show that RSPO2 induced a
significant increase in the EdU+ cells that undergo neuro-
genesis and become TH+ (Figures 5K and 5L). Thus, our
data indicate that RSPO2, in addition of promoting the dif-
ferentiation of neuroblasts into mDA neurons in mouse
and human, it promotes mDA neurogenesis in human
ESC cultures.
DISCUSSION
In this study we examine the expression and function of
the extracellular matrix (ECM) proteins of the RSPO family
and of SPON1, in themouse and humanVMand ESCs. Our
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analysis revealed that RSPO2, SPON1, and LGR5 are the
most significantly expressed spondins and receptors in
the VM in both the developing mouse and human VM.
However, we identified substantial differences in the cell
types expressing spondins. In the mouse, Rspo2 was found
in neuronal progenitors and neuroblasts and Spon1 in
radial glia 1–3; whereas, in the human VM, RSPO2 and
SPON1 were exclusively expressed in radial glia 1 and 3,
respectively. An additional difference between the two spe-
cies was that human RSPO2 was expressed in earlier cell
types (hRgl1), compared with mouse Rspo2, which was ex-
pressed in a rapid amplifying type of progenitor (mNProg)
and themedial postmitotic neuroblast (mNbM) (LaManno
et al., 2016). In agreement with this, we found an earlier
function of RSPO2 to promote mDA neurogenesis in hu-
man ESCs and a shared late function of RSPO2 in mouse
and human, to promote the differentiation of postmitotic
neuroblasts into mDA neurons. Unlike other systems in
which RSPOs control stem cell or progenitor maintenance
(de Lau et al., 2014) and SPON1 regulates differentiation
(Schubert et al., 2006), we did not observe any effect of
RSPOs on the number of Ki67+ cells or the total number
of EdU+ cells in human ESC cultures, or of SPON1 to pro-
mote differentiation. This is not totally surprising as the
midbrain floor plate expresses genes otherwise present in
completely different compartments (i.e., roof plate genes,
such as Lmx1a,Msx1,Wnt1, and Rspo2, together with floor
pate genes such as Shh, Foxa2,Wnt5a, and Spon1), resulting
in different regulatory networks and functions compared
with other brain regions or structures. One such example
is the presence of neurogenesis in the midbrain floor plate,
which represents an exception to the entire neural tube.
Notably our results indicate that roof plate RSPO2, as other
‘‘roof plate factors’’ in the VM (i.e., Lmx1a,Msx1, andWnt1;
see Arenas et al., 2015 for review) also regulates mDA
neurogenesis.
UnderstandinghumanmDAneurondevelopment in vivo
and implementing such knowledge to protocols for the dif-
ferentiation of human ESCs into mDA neurons is currently
considered as the basis for refining and improving existing
protocols to prepare cells for cell replacement therapy. In
the past, the implementation of correct levels of Wnt
signaling for the specification of midbrain floor plate pro-
genitors has been critical for the development of protocols
allowing the transplantation of mDA progenitors capable
of efficiently differentiating into functional mDA neurons
in vivo (Kriks et al., 2011; Nolbrant et al., 2017). These pro-
tocols are still susceptible to improvement by implement-
ing new factors and knowledge, such as additional compo-
nents of the Wnt signaling pathway recently reported in
the developing mouse and human VM (Toledo et al.,
2017b) or the Wnt modulator that we hereby report,
RSPO2. As an ECM protein, RSPO2may function to define,
together with other ECM proteins, the niche where human
mDA neurogenesis takes place. Indeed, our results indicate
that by manipulating the extracellular compartment it is
possible to control essential intracellular functions such
as mDA neurogenesis and differentiation in human ESC
cultures. Moreover, RSPO2 may also play a role in mDA
neuron subtype specification, as suggested by the increase
in ALDH1A1 in mouse and human cell expression by
RSPO2 treatment (our results) or the decrease in its protein
Figure 5. Role of RSPO2 in Differentiation of Human ESCs
(A) Violin plots generated from single-cell RNA-seq data of the developing human VM. RSPO2 and SPON1 expression levels are shown across
all cell types in the human VM. Right axis shows absolute molecule counts. Gray, enriched over baseline with posterior probability >99.8%.
Cell types with enriched expression: hRgl1,3, radial glia-like cells 1,3. For the rest of the cell-type nomenclature, see La Manno et al.
(2016).
(B) Protocol for the dopaminergic differentiation of human ESCs.
(C) Human ESC cultures after 28 days stained for various DA lineage markers: EN1, OTX2, TH, and ALDH1A1. Scale bars, 50 mm.
(D) Expression of DA markers (OTX2, NR4A2, EN1, PITX3, and ALDH1A1) by qPCR between Vehicle- and RSPO2-treated cultures after 28 days
(unpaired t test, n = 3, *p < 0.05, **p < 0.01).
(E) Human ESC cultures after 28 days stained for markers of apoptosis (aC3), proliferation (KI67), markers of DA lineage (NR4A2 and TH).
Scale bars, 50 mm.
(F) The number of apoptotic cells (aC3+/DAPI) was no modified by RSPO2 treatment.
(G) The number of proliferating cells (KI67+/DAPI) was the same in both conditions.
(H) The number of NR4A2+ cells were not significantly different in RSPO2-treated and control cultures (t test, n = 3, p = 0.09).
(I) A significant increase in the total number of DA neurons (TH+/DAPI) was detected in RSPO2-treated human ESC cultures (t test, n = 3,
*p = 0.01).
(J) RSPO2 treatment increases the proportion of NR4A2+ cells that become TH+ in human ESC cultures (t test, n = 3, *p = 0.02).
(K) RSPO2 increases DA neurogenesis in human ESC cultures, as assessed by the incorporation of EdU in TH+ cells at day 28, arrowheads.
Scale bars, 50 mm.
(L) Quantification of the number of EdU/TH double-positive cells showed that RSPO2 significantly increases DA neurogenesis in human ESC
cultures (t test, n = 3, *p = 0.03).
See also Figure S4.
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levels in RSPO2/ mice (Hoekstra et al., 2013). While
much attention has been devoted to the role of transcrip-
tion factors and morphogens in development and stem
cell biology, only recently have we started to implement
the knowledge of what can be considered as the third pillar
of development: the ECM. Indeed, ECM proteins are gain-
ing increasing interest as the accrued knowledge of their di-
versity (reviewed in Murphy-Ullrich and Sage, 2014) and
functions begin to accumulate (Ganapathy et al., 2016;
Long et al., 2016; Wiese and Faissner, 2015). In this
context, our study identifies RSPO2 as a matricellular
component capable of promoting mDA neurogenesis and
differentiation. Our results thus pave the way for RSPO2
to be used to improve current human ESC preparations
for regenerative medicine or drug discovery for Parkinson
disease.
EXPERIMENTAL PROCEDURES
Animals
Wild-type (WT) CD-1 (Charles River, Germany) orWT Swiss (Janv-
ier Labs) mice were mated overnight, and the noon of the day
of a plug was considered E0.5. Mice were shipped as pregnant
females, and then housed and treated in accordance with the
guidelines of the local ethics committee (Stockholm’s Norra
Djurfo¨rso¨ksetisks Na¨md. Ethical numbers N145/09, N273/11,
N326/12, and N158/15).
Tissue Collection
After CD-1 mice were killed and embryos collected at different
stages, embryonic heads were fixed in 4% paraformaldehyde
(PFA) for at least 6 hr at +4C. Then tissue was washed briefly
in PBS and processed to 30% sucrose/PBS solution overnight
at +4C. Tissue was then embedded in O.C.T. (TissueTek) and
stored at 80C until sectioning. Sectioning was performed on a
Leica cryostat at 16 mm sections used for IHC analysis.
qPCR
Mice
RNA was isolated from dissected WT CD-1 mice VM from various
time points. RNA was extracted using RNeasy Mini Kit (QIAGEN).
SYBR green real-time qPCR assay was performed as described
previously (Rawal et al., 2006; Sacchetti et al., 2009).
Mouse Primary Culture
Total RNAwas isolated using RNeasy Kit (QIAGEN), and cDNAwas
made with cDNA SuperScript II Reverse Transcriptase Kit (Thermo
Fisher Scientific). Specific genes were amplified using Fast SYBR
Green Master Mix Kit (Thermo Fisher Scientific). Real-time PCR
was performed using fast protocols on a 7500 Fast Real-Time PCR
system (Thermo Fisher Scientific). GAPDH was used to normalize
the expression of mRNA.
Human ESC Culture
Total RNA was extracted from cells at day 28 of culture using
the NucleoSpin RNA extraction kit (Macherey-Nagel, cat. no.
740955.10) as per the manufacturer’s instructions. Quantity and
quality of RNAwas determined using aNanoDrop Lite Spectropho-
tometer (Thermo Fisher Scientific). cDNA was synthesized from
500 ng of RNA using SuperScript II Reverse Transcriptase (Invitro-
gen). SYBR green (QIAGEN) qPCR assays were performed using a
LightCycler 480II (Roche) and primers purchased from Sigma
(sequences in table). A 5-fold serial dilution standard curve was
generated for each primer to generate efficiency curves and relative
expression levels were obtained using the Pfaffl method (Pfaffl,
2001). HPRT was used as the housekeeping gene.
Primer sequences in Table S1.
RNA-Seq Datasets and Gene Expression Profiles
Gene expression datawere obtained throughprevious datasets. For
tissue TruSeq datasets, see Toledo et al. (2017a), and for single-cell
RNA-seq datasets see La Manno et al. (2016).
Primary Cell Culture
Plates were coated with poly-D-lysine and VMs were dissected out
fromE11.5WTembryos into ice-cold PBS. VMswere dissociated by
trituration using flame-polished glass Pasteur pipettes. Cells were
plated at a density of 150,000 cells/cm2. They were grown in N2
medium (1:1 F12:MEM, HEPES, N2 supplement, and glutamine;
Thermo Fisher Scientific) with additional 6 mg/mL glucose and
3 mg/mL AlbuMAXI BSA. Cells were treated with for 3 days with
different recombinant proteins (recombinant human F-spondin
protein 80 ng/mL [cat. no. 3135-SP], recombinant human R-spon-
din 2 protein 160 ng/mL [cat. no. 3266-RS], recombinant mouse
R-spondin 1 protein 160 ng/mL [cat. no. 3474-RS], recombinant
mouse Dkk-1 protein 100 ng/mL [cat. no. 5897-DK], and recombi-
nant human/mouseWnt-5a protein 100 ng/mL [cat. no. 645-WN],
all resuspended in 0.1% BSA/PBS; R&D Systems) or vehicle (0.1%
BSA/PBS). Cells were then fixed with 4% PFA and processed for
staining.
Mouse ESC Culture
Mouse ESC (R1) cultures were co-cultured with immortalized PA6
feeder cells. Differentiation of mouse ESCs was done following
a 14-day in vitro protocol (Barberi et al., 2003). Mouse ESCs were
maintained in proliferation medium (Knockout-DMEM, 15%
Knockout Serum Replacement, 2 mM L-glutamine, 10,000 U/mL
penicillin/streptomycin [all from Life Technologies], 1% non-
essential amino acids [VWR], 0.1 mM b-mercaptoethanol [Sigma],
and 1,000 U/mL leukemia inhibitory factor [LIF] [ESGRO;
Chemicon/Millipore]). Mouse ESCs were plated (150 cells/cm2)
on a confluent mitomycin C-treated PA6 feeder cell layer in
24-well plates in proliferation medium without LIF. At day 5,
sonic hedgehog (SHH) (200 ng/mL) and fibroblast growth factor 8
(FGF8) (25–100 ng/mL) were added to the medium. After 8 days,
N2 mediumwas used in the presence of SHH, FGF8, and basic FGF
(10 ng/mL). From day 11 to 14, N2 medium containing ascorbic
acid (AA) (200 mM) (Sigma), brain-derived neurotrophic factor
(BDNF) (20 ng/mL) (R&D Systems), and glial cell line-derived
neurotrophic factor (GDNF) (10 ng/mL) (R&D Systems) was
used. Treatments with recombinant spondins or vehicle started
at day 5 and lasted up until day 11, concentrations the same
as primary cultures. Cells were then fixed with 4% PFA and
processed for staining.
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Human ESC Culture
Undifferentiated RC17 ESCs (passages 33–54, Roslin Cells, hPSC
reg. no. RCe021-A) were maintained in E8 medium (A1517001)
on Geltrex (1%, 12760021)-coated plates and passaged weekly
with EDTA (0.5 mM). To start differentiation (day 0), human ESC
colonies were detached using EDTA (0.5 mM) and placed in non-
treated 60-mmculture dishes in differentiationmediumconsisting
of DMEM:F12/Neurobasal (1:1), N2 supplement (1:100), B27 sup-
plement (1:50), SB431542 (10 mM, Tocris Biosciences), rhnoggin
(100 ng/mL, R&D Systems), SHH-C24II (200 ng/mL, R&D
Systems), and CHIR99021 (0.9 mM, Tocris Biosciences). Medium
was changed once on day 2. The resultant embryoid bodies were
collected on day 4 and placed on polyornithine (PO)-, fibronectin
(Fn)-, and laminin (Lm)-coated plates in reduced N2 (1:200) and
B27 (1:100) condition. Growth and patterning factors were
removedon day 9with the cultures kept inDMEM:F12/Neurobasal
(1:1), N2 supplement (1:200), and B27 supplement (1:100). On
day 11 of differentiation, the cell clusters were dissociated to single
cells with accutase and replated onto dry PO/Fn/Lm-coated plates
in Neurobasal, B27 (1:50), BDNF (20 ng/mL), GDNF (10 ng/mL),
AA (200 mM), and db-cAMP (0.5mM, Sigma). Fromday 14, cultures
were treated with RSPO2 (1 mg/mL, R&D Systems) up until day 28,
when they were fixed in 3.7% PFA for 30 min. EdU pulse was
administered on day 23 for 24 hr to capture all the dividing cells.
Cells were then fixed 4 days later on day 28. All culture reagents
are from Invitrogen unless otherwise stated here or previously.
IHC/ICC
Cells and tissue were fixed in 4% PFA, washed in PBS and
blocked in PBTA (PBS, 5% normal goat/donkey serum [Jackson
ImmunoResearch], 0.1% Triton X-100, and 1% BSA) for 1 hr at
room temperature (RT). Primary antibodies were diluted in 0.1%
Triton X-100 and 1% BSA/PBS, and incubations were carried out
overnight at 4C.
Antibodies used were: bIII-tubulin (1:1,000, Promega, G7121),
cleaved caspase-3 (1:200, Cell Signaling Technology, 9661S),
NR4A2 (1:100, Santa Cruz, sc-991), TH (1:1,000, Millipore,
AB152), TH (1:1,000, Pel-Freez, P40101), NES (1:500, BD Biosci-
ences, 556309), LGR5 (1:200, Atlas Antibodies, HPA012530),
LGR4 (1:50, Santa Cruz Biotechnology, sc-292344), RSPO2
(1:500, Atlas Antibodies, HPA025764), SOX2 (1:200, R&D Systems,
MAB2018), Ki67 (1:200, Thermo Fisher Scientific, MA5-14520),
EN1 (Abcam, ab70993), OTX2 (R&D Systems, AF1979), ALDH1A1
(Abcam, ab23375), and click-iT EdU (Invitrogen, C10337). Corre-
sponding secondary antibodies were Alexa Fluor Dyes (Invitrogen)
(1:1,000) and incubated at RT for 1 hr. Cells were counterstained
with DAPI (Thermo Fisher Scientific, D1306) or Hoechst 33258
(Sigma). Cells were then washed and kept in PBS and sections
were washed and mounted with Mounting Medium (Dako).
IHC/ICC were captured on an Olympus FV1000 confocal micro-
scope, a Zeiss LSM510 confocalmicroscope, or a Zeiss Axioplanmi-
croscope. Human ESC images were captured on either an operetta
high-content imaging system (PerkinElmer) or an SP8 confocal
microscope (Leica). Human ESCs were counted using an auto-
mated software package (Columbus). Images and figure layouts
were processed in FIJI (Schindelin et al., 2012), Adobe Photoshop,
and Adobe Illustrator.
Cell Counts and Statistical Analyses
All experiments were performed as technical duplicates (two
wells per treatment) and three independent biological replicates.
Analysis of images was performed from at least five images of
each well. For mouse ESC cultures, cells were counted within a
bIII-tubulin area (defined as an area just outside of cell clusters
where nuclei could be distinguished) with the aid of FIJI image pro-
cessing software (Schindelin et al., 2012). Statistical test performed
include two-tailed t test and/or ANOVA, deviations are SDs unless
otherwise stated.
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